Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $148.2 million.

  • Mirum Pharmaceuticals' Accumulated Expenses rose 4153.96% to $148.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $148.2 million, marking a year-over-year increase of 4153.96%. This contributed to the annual value of $111.9 million for FY2024, which is 4250.99% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Accumulated Expenses stood at $148.2 million for Q3 2025, which was up 4153.96% from $127.1 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Accumulated Expenses peaked at $148.2 million during Q3 2025, and registered a low of $20.8 million during Q2 2021.
  • Over the past 5 years, Mirum Pharmaceuticals' median Accumulated Expenses value was $54.0 million (recorded in 2022), while the average stood at $68.6 million.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Accumulated Expenses soared by 23731.06% in 2021 and then tumbled by 1262.57% in 2022.
  • Mirum Pharmaceuticals' Accumulated Expenses (Quarter) stood at $30.7 million in 2021, then surged by 75.82% to $54.0 million in 2022, then surged by 45.4% to $78.5 million in 2023, then surged by 42.51% to $111.9 million in 2024, then surged by 32.39% to $148.2 million in 2025.
  • Its Accumulated Expenses stands at $148.2 million for Q3 2025, versus $127.1 million for Q2 2025 and $115.9 million for Q1 2025.